Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy

Inclusion Criteria

• •Prior/Concurrent Therapy Criteria
• •1. Patients must be initiating a new treatment regimen for pancreatic cancer at the time of their initiation in the study
• •2. Patients must have cytologic or histologic confirmation of pancreatic cancer
• •3. Patients must have measurable radiographic evidence of metastatic disease
• •4. Patients must be ≥18 years of age
• •5. Patients must have an ECOG Performance Status 0-2.
• •6. Patients must have adequate organ function for delivery of chemotherapy as evidenced by the following: Hgb ≥8 g/dL, platelets ≥ 75
• •7. Patients must not have renal dysfunction that would prevent administration of IV contrast for radiographic assessment.
• •Regulatory Criteria
• •8. Patients must be informed of the investigational nature of this study and must sign and give written informed consent for this protocol in accordance with institutional and federal guidelines.
• •9. Patients of all races, genders, \& ethnicities are eligible.